The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial

@inproceedings{Wu2013TheEO,
  title={The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial},
  author={Jian-Feng Wu and Lixin Zhou and Jiyun Liu and Gang Ma and Qiuye Kou and Zhi-jie He and Juan Chen and Bin Ou-Yang and Min-ying Chen and Yinan Li and Xiaoqin Wu and Baochun Gu and Lei Chen and Zijun Zou and Xinhua Qiang and Yuanyuan Chen and Ai-hua Lin and Guanrong Zhang and Xiangdong Guan},
  booktitle={Critical care},
  year={2013}
}
INTRODUCTION Severe sepsis is associated with a high mortality rate despite implementation of guideline recommendations. Adjunctive treatment may be efficient and require further investigation. In light of the crucial role of immunologic derangement in severe sepsis, thymosin alpha 1 (Tα1) is considered as a promising beneficial immunomodulatory drug. The trial is to evaluate whether Tα1 improves 28-day all-cause mortality rates and immunofunction in patients with severe sepsis. METHODS We… CONTINUE READING